Table 1.

Forearm blood flow and vasodilation during exercise with balloon inflation

			Inflation		Deflation
	Baseline	Exercise (Control)	Nadir	Steady state	Acute	Steady state
Protocol 1
20% MVC (no drug)
FBF, ml/min	95 ± 16	461 ± 67*	195 ± 29†	399 ± 51§	573 ± 89§b	554 ± 77§
FVC, ml·min−1·100 mmHg−1	107 ± 17	519 ± 73*	330 ± 46†	512 ± 66§	608 ± 83§	597 ± 74§
20% MVC (Ketorolac)
FBF, ml/min	83 ± 15	423 ± 56*	202 ± 37‡	347 ± 46a,d	596 ± 113§b	498 ± 76§
FVC, ml·min−1·100 mmHg−1	93 ± 17	473 ± 61*	305 ± 51‡	448 ± 58a,d	638 ± 106‡§b	542 ± 75§
20% MVC (Ketorolac + l-NMMA)
FBF, ml/min	73 ± 13d	400 ± 66*	193 ± 35‡	296 ± 45d	567 ± 166§b	424 ± 59a,d
FVC, ml·min−1·100 mmHg−1	81 ± 14d	433 ± 61*	304 ± 49‡	379 ± 58c	591 ± 150§b	452 ± 51d
Protocol 2
20% MVC (no drug)
FBF, ml/min	77 ± 9	447 ± 50*	202 ± 26†	409 ± 45a	624 ± 120§b	496 ± 51§
FVC, ml·min−1·100 mmHg−1	89 ± 10	480 ± 45*	290 ± 25‡	465 ± 32a	649 ± 123§b	517 ± 47§
20% MVC (l-NMMA)
FBF, ml/min	60 ± 8d	421 ± 44*	188 ± 23†	348 ± 40a,d	522 ± 90§b	491 ± 56§b
FVC, ml·min−1·100 mmHg−1	67 ± 10d	451 ± 45*	278 ± 25†	389 ± 41d	541 ± 90§b	503 ± 52§
20% MVC (l-NMMA + Ketorolac)
FBF, ml/min	50 ± 6d	414 ± 48*	177 ± 29†	332 ± 52d	529 ± 103§b	482 ± 62§
FVC, ml·min−1·100 mmHg−1	54 ± 9d	441 ± 54*	255 ± 34‡	369 ± 57d	531 ± 97§b	493 ± 66§

Values are means ± SE.

FBF, forearm blood flow; FVC, forearm vascular conductance; l-NMMA, N^G-monomethyl-l-arginine; MVC, maximal voluntary contraction.

^*P < 0.001 vs. baseline.

^†P < 0.01 vs. exercise (control).

^‡P < 0.05 vs. exercise.

^§P < 0.01 vs. nadir.

^aP < 0.05 vs. nadir.

^bP < 0.05 versus inflation (steady state).

^cP < 0.05 vs. other trials.

^dP < 0.05 vs. no drug trial.